Biotech News

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma (ATYR)aTyr PharmaFDA / regulatory

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026. SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Related news

ATYRaTyr Pharma2026-10-29 12:00 EST

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

BMYBMYBristol-Myers Squibb Company2026-09-30 21:32 EST

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

REGNRegeneron Pharmaceuticals2026-11-18 23:03 EST

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

ATYRaTyr Pharma2026-11-11 13:00 EST

aTyr Pharma to Participate in Upcoming Investor Conferences

SABSSAB Biotherapeutics2026-10-13 12:30 EST

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

ANABAnaptysBio, Inc.2026-10-19 18:18 EST

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

HCWBHCW Biologics2026-10-09 13:00 EST

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

TLSATiziana Life Sciences2026-09-30 11:00 EST

Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

HCMHUTCHMED2026-09-29 00:00 EST

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

REGNRegeneron Pharmaceuticals2026-11-17 12:00 EST

Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

Stock data

Close
3.69 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States